Global RNAi Technology Market - Growth, Trends And Forecasts (2017 - 2022)

The global market for RNAi technology is estimated to be USD 8.7 billion in 2014 and is expected to reach USD21.9 billion by 2019, growing at a CAGR of 20.19%

RNA interference (RNAi) is a natural process of treating forms of cancer and other diseases by post-transcriptional silencing of genes by small fragments of the nucleic acid. However, the path of RNAi therapies to the clinic has been more like a roller-coaster ride. RNAi technology can be helpful in providing target specificity to the proteins that lack the enzymatic pocket necessary for binding.

Global RNAi Technology Market-Market Dynamics

The major drivers for the growth of the market are improving synthetic delivery carriers and chemical modifications to RNA, increasing genetic and metabolic disorders including diseases like cancer and increasing applications in molecular diagnostics, particularly that of cancer. However, the market is facing major challenges because of strict FDA regulations and the fact that RNA is potentially immunogenic and inherently unstable, which causes major problems for the research and development of drugs. Greatly expanding the number of druggable disease targets and potentially streamlining drug development are the market growth opportunities in the coming years.

RNAi technology is showing promise in the treatment of viral infections like hepatitis B virus (HBV), which affects more than 300 million worldwide, killing at least 780,000 annually through liver scarring, liver failure, and liver cancer. There has been a shift in strategic focus of RNAi innovators from RNAi triggers to delivery. Small RNAi therapeutics innovator (pure-play) companies and Big Pharma remain the industry's two protagonists, although medium-sized pharmaceutical companies, including those in Asian countries, have taken some of the space vacated by Big Pharma. RNAi technology has application in different sectors like drug discovery and development and therapeutics. Therapeutics is the major growing sector owing to the increased demand for treatment of cancer and liver disorders.

The market is segmented by type of application (drug discovery and development, therapeutics, and others), by therapeutics (oncology, ocular disorders, respiratory disorders, liver diseases, and neuronal disorders) and geography (North America, Europe, and Asia-Pacific).

The key players in the market are focused on the expansion of their business by launching new products and extending the product line. Mergers and acquisitions of small and medium-sized manufacturers to enter the overseas market is another strategy adopted by multinational players. RNAi technologies market is still at their nascent stage but companies are keen on taking this market to a higher level.

Some of the key players in the market are:

Alnylam Pharmaceuticals

Benitec Biopharma Ltd

Filmtec Corporation

Ionis Pharmaceuticals

Quark Pharmaceuticals Inc.

RXI Pharmaceuticals

What the Report Offers

Market definition of RNAi technology market along with identification of key drivers and restraints for the market.

Market analysis for the RNAi technology, with region-specific assessments and competition analysis on a global and regional scale.

Identification of factors instrumental in changing the market scenario, rising prospective opportunities and identification of key companies that can influence the market on a global and regional scale.

Extensively researched competitive landscape section with profiles of major companies along with their market share.

A comprehensive list of key market players along with the analysis of their current strategic interests and key financial information.

An exhaustive understanding of the worldwide market for RNAi technology.

A comprehensive analysis of the major trends, innovations and associated prospects for market growth over the coming half a decade.

An ideal opportunity for industry consultants and other interested and allied parties to gain a critical insight into the factors driving and restraining the market, in addition to opportunities offered.

Wide-ranging information provided about the leading market players and the major strategies adopted by them.


1.1 Market Definition

1.2 Market Size Estimation


2.1 Market Share Estimation

2.2 Key Data from Secondary Sources

2.3 Key Data from Primary Sources


4.1 Introduction

4.2 Market Dynamics

4.2.1 Drivers Improving synthetic delivery carriers and chemical modifications to RNA Increasing genetic and metabolic disorders Increasing applications in molecular diagnostics, particularly that of cancer

4.2.2 Restraints Strict FDA regulations RNA is inherently unstable, potentially immunogenic.

4.2.3 Opportunities Greatly expanding the number of druggable disease targets and potentially streamlining drug development

4.3 Market Share Analysis, By Key Players


5.1 Value Chain Analysis

5.2 Porter's Five Forces Analysis

5.2.1 Bargaining power of Buyers

5.2.2 Bargaining power of Suppliers

5.2.3 Degree of Competition

5.2.4 Threat of new entrants

5.2.5 Threat of Substitutes


6.1 By Application

6.1.1 Drug discovery and development

6.1.2 Therapeutics

6.1.3 Others

6.2 By Therapeutics

6.2.1 Oncology

6.2.2 Ocular Disorders

6.2.3 Respiratory Disorders

6.2.4 Liver Diseases Hepatitis B& C Autoimmune Hepatitis

6.2.5 Neuronal Disorders

6.2.6 Others

7. Geographical Analysis

7.1 North America

7.1.1 US

7.1.2 Canada

7.1.3 Mexico

7.2 Europe

7.2.1 UK

7.2.2 France

7.2.3 Germany

7.2.4 Spain

7.2.5 Italy

7.3 Asia-Pacific

7.3.1 India

7.3.2 China

7.3.3 Japan

7.3.4 Rest of Asia-Pacific

7.4 Row

8. RNAi Market Pipeline Analysis

8.1 Pipeline Products

8.2 Therapeutic Deals

9. Competitive Landscape

9.1 Introduction

9.2 New Product Launch

9.3 Agreements, Partnerships, Collaborations & Contracts

9.4 Expansion

9.5 Mergers & Acquisitions

10. Company Profiles

10.1 Alnylam Pharmaceuticals

10.2 Quark Pharmaceuticals Inc.

10.3 Benitec Biopharma Ltd

10.4 Isis Pharmaceuticals

10.5 RXI Pharmaceuticals

10.6 Filmtec Corporation

10.7 Silence Therapeutics

10.8 Merck (Sirna)

10.9 Tekmira Pharmaceuticals Corporation

10.10 Qiagen

10.11 Invitrogen

10.12 Ambion

Content are not available

Choose License Type